Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hypertens. May 23, 2015; 5(2): 63-73
Published online May 23, 2015. doi: 10.5494/wjh.v5.i2.63
Published online May 23, 2015. doi: 10.5494/wjh.v5.i2.63
Progress in neuregulin/ErbB signaling and chronic heart failure
Hong-Kun Yin, Xin-Yan Li, Zheng-Gang Jiang, Ming-Dong Zhou, Zensun (Shanghai) Sci and Tech Co., Ltd., Zhangjiang Hi-tech Park, Shanghai 201203, China
Author contributions: Yin HK wrote the manuscript; Li XY, Jiang ZG and Zhou MD revised the manuscript.
Conflict-of-interest: The authors declare that they have no conflicts of interest related to this work.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Ming-Dong Zhou, PhD, Zensun (Shanghai) Sci and Tech Co., Ltd., Zhangjiang Hi-tech Park, No. 68 Ju Li Road, Shanghai 201203, China. mdzhou@zensun.com
Telephone: +86-21-50802627 Fax: +86-21-50802621
Received: September 28, 2014
Peer-review started: September 29, 2014
First decision: January 20, 2015
Revised: March 10, 2015
Accepted: April 16, 2015
Article in press: April 18, 2015
Published online: May 23, 2015
Peer-review started: September 29, 2014
First decision: January 20, 2015
Revised: March 10, 2015
Accepted: April 16, 2015
Article in press: April 18, 2015
Published online: May 23, 2015
Core Tip
Core tip: Neuregulin (NRG)-1/ErbB signaling plays a critical role in the development of the heart and the maintenance of cardiac function. In both pre-clinical and clinical studies, NRG-1 has demonstrated efficacy as a therapeutic agent for the treatment of heart failure. In model animals and clinical trials, short-term treatment with recombinant NRG-1 protein results in a long-term beneficial effect. Here, the mechanisms underlying the therapeutic effects of NRG-1 during heart failure are reviewed. The results indicate that NRG-1 induces a cardiac reverse remodeling process through the initiation of changes in both cell metabolism and epigenetic modification.